Skip to main content
Erschienen in: Pediatric Surgery International 3/2016

01.03.2016 | Original Article

Analysis of clinical features and outcomes for inflammatory myofibroblastic tumors in China: 11 years of experience at a single center

verfasst von: Zuopeng Wang, Xiaolong Zhao, Kai Li, Wei Yao, Kuiran Dong, Xianmin Xiao, Shan Zheng

Erschienen in: Pediatric Surgery International | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Inflammatory myofibroblastic tumor (IMT) is a rare benign neoplasm. The purpose of this study was to review the clinical characteristics, imaging and pathological features, and outcomes of children with IMTs from a single center in China.

Methods

A retrospective file review was conducted involving 23 cases of pathologically confirmed IMTs treated at the Children’s Hospital between April 2003 and April 2014.

Results

The tumor locations included multiple anatomic sites, as follows: abdomen or pelvis (n = 17); lungs (n = 2); head and neck (n = 1); trunk (n = 1); and extremities (n = 2). The tumors were associated with various clinical presentations. The predominant symptoms included an anemic appearance, fevers, and an asymptomatic mass. Computed tomography scanning showed solid, heterogeneous, well-demarcated masses; the appearance of enhancement was variable. MRI appeared hypointense on T1-weighted images and hypointense or hyperintense on T2-weighted images. Immunohistochemical staining revealed anaplastic lymphoma kinase was negative in 11 of 13 cases tested. One patient quit treatment for the unresectable mass after biopsy and died 2 years later, and another patient with incompletely resection is alive at 30 months following chemotherapy. The remaining 21 cases had complete resections; one patient died due to a recurrence, and the other 20 patients survived and were tumor free. The follow-up ranged from 7 to 141 months, with a mean of 56 months. The 3-year OS was 88 % (95 % CI, 57–97 %).

Conclusions

IMT is a benign neoplasm that rarely presents with malignant features. Complete resection is curative in most patients. ALK+ is variable for diagnosis. Close follow-up is necessary for patients who undergo surgical resection.
Literatur
1.
Zurück zum Zitat Mehta B, Mascarenhas L, Zhou S, Wang L, Venkatramani R (2013) Inflammatory myofibroblastic tumors in childhood. Pediatr Hematol Oncol 30:640–645CrossRefPubMed Mehta B, Mascarenhas L, Zhou S, Wang L, Venkatramani R (2013) Inflammatory myofibroblastic tumors in childhood. Pediatr Hematol Oncol 30:640–645CrossRefPubMed
2.
Zurück zum Zitat Nagarajan S, Jayabose S, McBride W, Prasadh I, Tanjavur V, Marvin MR, Rodriguez-Davalos MI (2013) Inflammatory myofibroblastic tumor of the liver in children. J Pediatr Gastroenterol Nutr 57:277–280 Nagarajan S, Jayabose S, McBride W, Prasadh I, Tanjavur V, Marvin MR, Rodriguez-Davalos MI (2013) Inflammatory myofibroblastic tumor of the liver in children. J Pediatr Gastroenterol Nutr 57:277–280
3.
Zurück zum Zitat Cook JR, Dehner LP, Collins MH, Ma Z, Morris SW, Coffin CM, Hill DA (2001) Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol 25:1364–1371CrossRefPubMed Cook JR, Dehner LP, Collins MH, Ma Z, Morris SW, Coffin CM, Hill DA (2001) Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol 25:1364–1371CrossRefPubMed
4.
Zurück zum Zitat Diop B, Konate I, Ka S, Sall I, Fall D, Dieng M, Wone Y (2011) Mesenteric myofibroblastic tumor: NSAID therapy after incomplete resection. J Visc Surg 148:e311–e314CrossRefPubMed Diop B, Konate I, Ka S, Sall I, Fall D, Dieng M, Wone Y (2011) Mesenteric myofibroblastic tumor: NSAID therapy after incomplete resection. J Visc Surg 148:e311–e314CrossRefPubMed
5.
Zurück zum Zitat Kovach SJ, Fischer AC, Katzman PJ, Salloum RM, Ettinghausen SE, Madeb R, Koniaris LG (2006) Inflammatory myofibroblastic tumors. J Surg Oncol 94:385–391CrossRefPubMed Kovach SJ, Fischer AC, Katzman PJ, Salloum RM, Ettinghausen SE, Madeb R, Koniaris LG (2006) Inflammatory myofibroblastic tumors. J Surg Oncol 94:385–391CrossRefPubMed
6.
Zurück zum Zitat Mattei P, Barnaby K (2008) Rapid regression of duodenal inflammatory myofibroblastic tumor after intravenous ketorolac: case report and review of the literature. J Pediatr Surg 43:1196–1199CrossRefPubMed Mattei P, Barnaby K (2008) Rapid regression of duodenal inflammatory myofibroblastic tumor after intravenous ketorolac: case report and review of the literature. J Pediatr Surg 43:1196–1199CrossRefPubMed
7.
Zurück zum Zitat Fletcher CDM, Unni KK, Mertens F (2002) World Health Organization classification of tumors. Pathology and genetics of tumors of soft tissue and bone. IARC Press, Lyon, pp 48–106 Fletcher CDM, Unni KK, Mertens F (2002) World Health Organization classification of tumors. Pathology and genetics of tumors of soft tissue and bone. IARC Press, Lyon, pp 48–106
8.
Zurück zum Zitat Tao YL, Wang ZJ, Han JG, Wei P (2012) Inflammatory myofibroblastic tumor successfully treated with chemotherapy and nonsteroidals: a case report. World J Gastroenterol 18:7100–7103PubMedCentralCrossRefPubMed Tao YL, Wang ZJ, Han JG, Wei P (2012) Inflammatory myofibroblastic tumor successfully treated with chemotherapy and nonsteroidals: a case report. World J Gastroenterol 18:7100–7103PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Bertocchini A, Lo ZC, Callea F, Gennari F, Serra A, Monti L, de Ville DGJ (2011) Unresectable multifocal omental and peritoneal inflammatory myofibroblastic tumor in a child: revisiting the role of adjuvant therapy. J Pediatr Surg 46:e17–21 Bertocchini A, Lo ZC, Callea F, Gennari F, Serra A, Monti L, de Ville DGJ (2011) Unresectable multifocal omental and peritoneal inflammatory myofibroblastic tumor in a child: revisiting the role of adjuvant therapy. J Pediatr Surg 46:e17–21
10.
Zurück zum Zitat Coffin CM, Hornick JL, Fletcher CD (2007) Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 31:509–520CrossRefPubMed Coffin CM, Hornick JL, Fletcher CD (2007) Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 31:509–520CrossRefPubMed
11.
Zurück zum Zitat Karnak I, Senocak ME, Ciftci AO, Caglar M, Bingol-Kologlu M, Tanyel FC, Buyukpamukcu N (2001) Inflammatory myofibroblastic tumor in children: diagnosis and treatment. J Pediatr Surg 36:908–912CrossRefPubMed Karnak I, Senocak ME, Ciftci AO, Caglar M, Bingol-Kologlu M, Tanyel FC, Buyukpamukcu N (2001) Inflammatory myofibroblastic tumor in children: diagnosis and treatment. J Pediatr Surg 36:908–912CrossRefPubMed
12.
Zurück zum Zitat Yang X, Miao R, Yang H, Chi T, Jiang C, Wan X, Xu Y, Xu H, Du S, Lu X, Mao Y, Zhong S, Zhao H, Sang X (2014) A retrospective and comparative study of inflammatory myofibroblastic tumor of the liver. J Gastroenterol Hepatol 30:885–890 Yang X, Miao R, Yang H, Chi T, Jiang C, Wan X, Xu Y, Xu H, Du S, Lu X, Mao Y, Zhong S, Zhao H, Sang X (2014) A retrospective and comparative study of inflammatory myofibroblastic tumor of the liver. J Gastroenterol Hepatol 30:885–890
13.
Zurück zum Zitat Cessna MH, Zhou H, Sanger WG, Perkins SL, Tripp S, Pickering D, Daines C, Coffin CM (2002) Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod Pathol 15:931–938CrossRefPubMed Cessna MH, Zhou H, Sanger WG, Perkins SL, Tripp S, Pickering D, Daines C, Coffin CM (2002) Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod Pathol 15:931–938CrossRefPubMed
14.
Zurück zum Zitat Dong A, Wang Y, Dong H, Gong J, Cheng C, Zuo C, Lu J (2014) Inflammatory myofibroblastic tumor: FDG PET/CT findings with pathologic correlation. Clin Nucl Med 39:113–121PubMed Dong A, Wang Y, Dong H, Gong J, Cheng C, Zuo C, Lu J (2014) Inflammatory myofibroblastic tumor: FDG PET/CT findings with pathologic correlation. Clin Nucl Med 39:113–121PubMed
15.
Zurück zum Zitat Fernandez DLPG, Garcia AJ, Lechuga VM, Blanco MM (1999) Hepatic inflammatory pseudotumor: apropos a case with a response to steroid treatment. Gastroenterol Hepatol 22:14–17 Fernandez DLPG, Garcia AJ, Lechuga VM, Blanco MM (1999) Hepatic inflammatory pseudotumor: apropos a case with a response to steroid treatment. Gastroenterol Hepatol 22:14–17
16.
Zurück zum Zitat Coffin CM, Watterson J, Priest JR, Dehner LP (1995) Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol 19:859–872CrossRefPubMed Coffin CM, Watterson J, Priest JR, Dehner LP (1995) Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol 19:859–872CrossRefPubMed
17.
Zurück zum Zitat Janik JS, Janik JP, Lovell MA, Hendrickson RJ, Bensard DD, Greffe BS (2003) Recurrent inflammatory pseudotumors in children. J Pediatr Surg 38:1491–1495CrossRefPubMed Janik JS, Janik JP, Lovell MA, Hendrickson RJ, Bensard DD, Greffe BS (2003) Recurrent inflammatory pseudotumors in children. J Pediatr Surg 38:1491–1495CrossRefPubMed
18.
Zurück zum Zitat Lazure T, Ferlicot S, Gauthier F, Doz F, Couturier J, Fabre M, Bedossa P (2002) Gastric inflammatory myofibroblastic tumors in children: an unpredictable course. J Pediatr Gastroenterol Nutr 34:319–322CrossRefPubMed Lazure T, Ferlicot S, Gauthier F, Doz F, Couturier J, Fabre M, Bedossa P (2002) Gastric inflammatory myofibroblastic tumors in children: an unpredictable course. J Pediatr Gastroenterol Nutr 34:319–322CrossRefPubMed
Metadaten
Titel
Analysis of clinical features and outcomes for inflammatory myofibroblastic tumors in China: 11 years of experience at a single center
verfasst von
Zuopeng Wang
Xiaolong Zhao
Kai Li
Wei Yao
Kuiran Dong
Xianmin Xiao
Shan Zheng
Publikationsdatum
01.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Surgery International / Ausgabe 3/2016
Print ISSN: 0179-0358
Elektronische ISSN: 1437-9813
DOI
https://doi.org/10.1007/s00383-015-3840-7

Weitere Artikel der Ausgabe 3/2016

Pediatric Surgery International 3/2016 Zur Ausgabe

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.